Identifying people with acute lymphoblastic leukemia who are most suitable for treatment with inotuzumab ozogamicin: a plain language summary
Por:
Marks, DI, Cassaday, RD, Ribera, JM, Schuh, AC, Park, JH, Chiaretti, S and Stelljes, M
Publicada:
4 may 2025
Ahead of Print:
1 may 2025
Resumen:
Filiaciones:
Marks, DI:
Univ Hosp Bristol NHS Trust, Bristol, England
Cassaday, RD:
Univ Washington, Seattle, WA USA
Fred Hutchinson Canc Ctr, Seattle, WA USA
:
Inst Catala Oncol, Barcelona, Spain
Josep Carreras Res Inst, Barcelona, Spain
Schuh, AC:
Canc Clin Res Unit, Toronto, ON, Canada
Park, JH:
Mem Sloan Kettering Canc Ctr, New York, NY USA
Chiaretti, S:
Sapienza Univ Rome, Dept Translat & Precis Med, Rome, Italy
Stelljes, M:
Univ Munster, Munster, Germany
Bronze
|